Vitae Pharmaceuticals

  • About Us
    • Company Overview
    • Management Team
    • Scientific Advisory Groups
    • Board of Directors
    • Investors
    • News & Events
    • Careers
  • Pipeline
    • Overview
    • Chronic Kidney Disease
    • Diabetes
    • Alzheimer's Disease
    • Publications
  • Discovery
    • Overview
    • Capabilities
    • Network
  • Partnerships
  • Technology
    • Overview
    • CONTOUR® SBDD: Growth and Scoring
    • Structural Biology
  • Contact Us
    • Contact
    • Directions
 

About Us

  • Company Overview
    • A Note from the CEO
    • Our Approach
    • Overview of Results
    • Our Values
    • Business Strategy
  • Management Team
    • Jeffrey S. Hatfield
    • Richard Gregg, M.D.
    • Tina Fiumenero
    • Christine Brennan, Ph.D.
    • David A. Claremon, Ph.D.
    • Gerard M. McGeehan, Ph.D.
  • Scientific Advisory Groups
    • Eugene Shakhnovich, Ph.D.
    • William L. Jorgenson, Ph.D.
    • Michael Milburn, Ph.D.
    • Brian Shoichet, Ph.D.
    • Pierre Corvol, M.D., Ph.D.
    • Norman K. Hollenberg, M.D., Ph.D.
    • Domenic A. Sica, M.D.
  • Board of Directors
    • Peter Barrett, Ph.D.
    • Robert V. Gunderson, Jr.
    • Jeffrey S. Hatfield
    • Donald Hayden
    • Charles W. Newhall, III
    • Bryan Roberts, Ph.D.
    • James Tananbaum, M.D.
  • Investors
  • News & Events
  • Careers

Board of Directors

Peter Barrett, Ph.D.
Senior Partner, Atlas Venture

Robert V. Gunderson, Jr.
Senior Partner, Gunderson, Dettmer, Stough, Villeneuve, Franklin & Hachigian, LLP

Jeffrey S. Hatfield
President & Chief Executive Officer, Vitae Pharmaceuticals, Inc.

Donald Hayden
Chairman of the Board

Charles W. Newhall, III
General Partner, New Enterprise Associates

Bryan Roberts, Ph.D.
General Partner, Venrock Associates

James Tananbaum, M.D.
Chief Executive Officer of Foresite Capital Management

  • Terms of Use
  • Privacy Policy
© Vitae Pharmaceuticals     Website design: Hane Chow Inc.